ScreenerHero

BCTXBriaCell Therapeutics Corp.

NAS · US · Healthcare · Biotechnology · briacell.com
4.070USD+2.78%Mkt Cap: 35.41M $P/E: —

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap35.41M $
Enterprise Value10.91M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-30.68M $
Revenue/Share—
Last Price4.070 USD
Fiscal Year EndJul 2025
MR QuarterApr 2026
Employees—
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-10.08
PEG—
EV/EBITDA-0.34
EV/Revenue—
P/S—
P/B1.18
EPS (TTM)-0.84
EPS (Forward)-0.39
52W Range
3.38986% of range4.180
52W High4.180 USD
52W Low3.389 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-175.25%
ROA-90.84%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-24.13M $
CapEx (TTM)456.80K $
FCF Margin—
FCF Yield-56.60%
Net Debt-22.80M $
Net Debt/EBITDA0.71
Balance Sheet
Debt/Equity—
Current Ratio7.07
Quick Ratio6.35
Book Value/Sh3.318 USD
Cash/Share2.621 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateJan 2, 2020
Splits
Last Split1:10
Split DateAug 25, 2025
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.8.70M
Float7.86M
Insiders0.51%
Institutions6.39%
Short Interest
Short Ratio2.8d
Short % Float4.70%
Short % Out.4.69%
Shares Short408.29K
Short (prev mo.)380.15K
Technical
SMA 503.402 (+19.6%)
SMA 2005.153 (-21.0%)
Beta1.52
S&P 52W Chg18.16%
Avg Vol (30d)175.18K
Avg Vol (10d)119.37K
Technical Indicators
RSI (14)65.6
MACD0.0883
MACD Signal0.0266
MACD Hist.+0.0617
BB Upper3.957 USD
BB Middle3.541 USD
BB Lower3.125 USD
BB Width23.51%
ATR (14)0.2475 USD
Vol Ratio (20d)1.32x